A randomised controlled trial of longer-term clinical outcomes and cost-effectiveness of Standard And New Antiepileptic Drugs

Conditions

Epilepsy Nervous System Diseases Epilepsy

Catrin Tudur Smith, Sarah J Nevitt, D. E. Appelbe, Richard Appleton, Pete Dixon et al. (9 authors)

Trials2017-07-1127 citations

10.1186/s13063-017-2067-4

Risk of a seizure recurrence after a breakthrough seizure and the implications for driving: further analysis of the standard versus new antiepileptic drugs (SANAD) randomised controlled trial

Laura Bonnett, Graham Powell, Catrin Tudur Smith, Anthony G Marson

BMJ Open2017-07-0117 citations

10.1136/bmjopen-2017-015868

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.

Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR, SANAD Study group.

2007-03-01557 citations

10.1016/s0140-6736(07)60461-9

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.

Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR, SANAD Study group.

2007-03-01530 citations

10.1016/s0140-6736(07)60460-7

Interventions

Monotherapy with clinicians' first choice standard drug (carbamazepine or valproate) versus appropriate comparators from among the new antiepileptic drugs

Eligibility

Inclusion criteria

Inclusion criteria: Patients recently suffering seizures

Exclusion criteria

Exclusion criteria: Not provided at time of registration.

Design outcomes

Primary

Measure	Time frame
Primary outcomes will be retention time on randomised drug and time to one year remission of seizures.	—

Secondary

Measure	Time frame
Secondary outcomes will include psychosocial measures and impact on direct medical costs.	—

Countries

United Kingdom

Outcome results

None listed